AMES, Iowa, Nov. 9 /PRNewswire-FirstCall/ -- BioForce Nanosciences,
Inc., a wholly owned subsidiary of BioForce Nanosciences Holdings, Inc.
(OTC Bulletin Board: BFNH.OB), announced today the completion of a Nano
eNabler(TM) system sale to the Technology & Engineering Center at Harvard
Medical School. Funding for the purchase was provided by an award from the
National Human Genome Research Institute (NHGRI).
"The completion of this sale marks an important event for BioForce as
the company develops this new and exciting technology," notes Kerry Frey,
chief operating officer of BioForce Nanosciences. "We are working to
promote the unique opportunities that the Nano eNabler technology provides
to assist researchers working with smaller platforms."
Dale Larson, Director of the Technology and Engineering Center is
leading the use of the Nano eNabler system. His group is utilizing the
system to print very small femtoliter volumes of biomolecules onto
specially developed nanohole array sensors with sub-micron dimensions. This
technology is being developed for use in drug discovery and development,
biomarker screening, diagnostic assays, and homeland security applications.
The nanohole array sensing technology is a label-free detection system that
is very sensitive and highly multiplexed. The Nano eNabler system enables
the printing of many different capture agents on their chip, allowing
researchers to simultaneously study many different binding interactions
from one sample on one chip.
Michael Lynch, BioForce product manager for the Nano eNabler system
notes, "I am very pleased to be working with this key group of Harvard
Medical School researchers. BioForce is focused on marketing this unique
printing technology to researchers working in a variety of areas where
these smaller micron and sub-micron dimensions are standard. As biosensors
and nanosensors move from academic R&D into commercial product development,
our printing technology will be called upon to address the needs of the
About BioForce Nanosciences, Inc.
BioForce Nanosciences is a nanotechnology tools and applications
company, providing innovative and practical products that support the
growth of the nanotechnology industry. BioForce has spent more than a
decade on invention, research, and development of patented and
patent-pending nanotechnology products. The core technology is the Nano
eNabler(TM) bench-top molecular printer, a portal to new opportunities in
nanotechnology. The Nano eNabler printing system opens the door to new and
important applications in the biomedical and life sciences markets that
lead to improved quality of life. BioForce continues to target inventions
that further expand the reach of its proprietary technology and expand its
robust patent, trademark, and IP portfolio.
BioForce Nanosciences, Inc., the Practical Nanotechnology(TM) Company,
brings inventions to the marketplace that complement existing innovations,
licensing and acquisitions. BioForce is a wholly owned subsidiary of
BioForce Nanosciences Holdings, Inc. (OTC Bulletin Board: BFNH.OB). For
more information, visit www.bioforcenano.com.
This news release contains forward-looking information that may be
affected by certain risks and uncertainties, including those risks and
uncertainties described in the Company's most recent filings with the
Securities and Exchange Commission. The Company's actual results could
differ materially from such forward-looking statements. We assume no duty
to update these statements at any future date.
SOURCE BioForce Nanosciences, Inc.